NEW YORK -- Moderna will soon start a clinical trail for a next-generation booster that is effective against both the delta and omicron variants of the coronavirus, with the aim of delivering the shot this fall, the company's chief medical officer, Paul Burton, told Nikkei.
The vaccine developer is also planning to offer a shot that offers protection against both the seasonal flu and the coronavirus in 2023 as it sees COVID-19 as an endemic that humanity will have to grapple with for years to come.
